author-photo

Judith Bushong

Bristol-Myers Squibb

2

Papers

3

Citations

Citation Trend

Filter By

Papers (2) Sort By

Journal Conference Others

First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small Cell Lung Cancer: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial

2021 Journal of Thoracic Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Nivolumab (NIVO) plus ipilimumab (IPI) versus chemotherapy (chemo) as first-line (1L) treatment for advanced non-small cell lung cancer (NSCLC): 4-year update from CheckMate 227.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (3)